Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma
Korean Journal of Radiology · 2026
DOI: 10.3348/kjr.2026.0364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Radiology, 2026. Verfasst von Po-Hsun Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Yttrium Radioisotopes, Radioembolization, Therapeutic. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, Kaohsiung Chang Gung Memorial Hospital, Health and Welfare Surcharge of Tobacco Products.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the feasibility, safety, and treatment outcomes of single-session whole-liver yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with multifocal hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study included 37 patients (age, 23-86 years; median age, 60 years) with multifocal HCC (2-21 tumors; median, 9) and preserved liver function (Child-Pugh A) who underwent planned single-session whole-liver Y90 TARE between 2017 and 2024. Treatment was performed when no substantial liver parenchyma could be spared on pretreatment imaging and angiographic evaluation. Treatment planning was based on the findings of technetium-99m macroaggregated albumin single-photon emission computed tomography and partition-model dosimetry. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Overall survival, progression-free survival, and hepatic toxicity were also evaluated, with toxicity assessed on the basis of the occurrence of adverse events, Child-Pugh class change, and the development of ascites within 3-6 months. RESULTS: Patients were followed up for 1.4-49.0 months (median, 17.8 months). At 3 months, the objective response rate was 78.4%; the disease control rate was 94.6%; and complete response was noted in 11 patients (29.7%). Successful downstaging was achieved in 19 (51.4%) patients. The median overall survival was not reached, and the median progression-free survival was 23.5 months. The 2-year overall and progression-free survival rates were 78.3% and 46.8%, respectively. Eleven patients (29.7%) subsequently underwent surgery, including one resection and 10 living-donor liver transplantations. None of the patients showed grade 3 or 4 adverse events or radioembolization-induced liver disease. One patient with cirrhosis showed worsening of the Child-Pugh class with ascites. CONCLUSION: Single-session whole-liver Y90 TARE was feasible and showed acceptable hepatic safety in carefully selected patients with multifocal HCC and preserved liver function. It achieved high response and downstaging rates and may serve as a bridge to curative surgery in selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Liver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. y7192215@ms17.hinet.net.
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. prof.chengyufan@gmail.com.
ORCID-Profile: Po-Hsun Huang, Hsin-You Ou, Leung-Chit Tsang, Hsien-Wen Hsu, Wei-Xiong Lim, Tung-Liang Huang, Ching-Chun Weng, Yi Lu, Chien-Chin Hsu, Chao-Long Chen, Chun-Yen Yu, Yu-Fan Cheng
Förderung
- Ministry of Health and Welfare
- Kaohsiung Chang Gung Memorial Hospital
- Health and Welfare Surcharge of Tobacco Products
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Huang, P. H., Ou, H. Y., Tsang, L. C., Hsu, H. W., Lim, W. X., Huang, T. L., Weng, C. C., Lu, Y., Hsu, C. C., Chen, C. L., Yu, C. Y., & Cheng, Y. F. (2026). Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma. Korean Journal of Radiology. https://doi.org/10.3348/kjr.2026.0364
Vancouver
Huang PH, Ou HY, Tsang LC, Hsu HW, Lim WX, Huang TL, et al. Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma. Korean Journal of Radiology. 2026. doi:10.3348/kjr.2026.0364
BibTeX
@article{Huang2026,
author = {Huang, Po-Hsun and Ou, Hsin-You and Tsang, Leung-Chit and Hsu, Hsien-Wen and Lim, Wei-Xiong and Huang, Tung-Liang and Weng, Ching-Chun and Lu, Yi and Hsu, Chien-Chin and Chen, Chao-Long and Yu, Chun-Yen and Cheng, Yu-Fan},
title = {Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma},
journal = {Korean Journal of Radiology},
year = {2026},
doi = {10.3348/kjr.2026.0364}
}
EUVIMED